Serum immunoreactive trypsin and pancreatic lipase in primary biliary cirrhosis

V FONSECA, O EPSTEIN,* A KATRAK, D JUNGLEE, DP MIKHAILIDIS, N McINTYRE,* P DANDONA

From the Departments of Chemical Pathology and Human Metabolism, and *Medicine, Royal Free Hospital and School of Medicine, London

SUMMARY Immunoreactive trypsin concentration and pancreatic lipase activity were measured in the sera of 33 patients with primary biliary cirrhosis. Immunoreactive trypsin was increased (above the normal range) in 16 (48%) and pancreatic lipase activity in 18 (55%) patients. Both enzymes were increased in 10 (30%) patients. Twenty four patients (73%) had an increase of either one or both enzymes. There was a significant correlation between immunoreactive trypsin and pancreatic lipase activity. This abnormality was not related to treatment with D-penicillamine, the age of the patients, the stage of the disease, or the severity of cholestasis. Thus most patients with primary biliary cirrhosis have increased pancreatic enzyme activity and immunoreactive trypsin concentration in their sera. These data are indicative of damage to the exocrine pancreas. The cause of this damage is as yet unknown.

Abnormalities of exocrine pancreatic function have been previously described in primary biliary cirrhosis.1 Although basal trypsin concentrations in the duodenal juice of these patients were normal, the response to stimulation with secretin-pancreozymin was impaired.1 We have previously shown that serum immunoreactive trypsin concentrations and pancreatic lipase activity are abnormal in several disease states that affect the pancreas, with and without clinical manifestations of pancreatic deficit.2–11 As serum immunoreactive trypsin and pancreatic lipase activity have not previously been assessed in primary biliary cirrhosis, we investigated the respective concentration and activity of these enzymes in this condition. We also assessed whether serum immunoreactive trypsin and pancreatic lipase activity correlated with severity of the liver disease and whether treatment with D-penicillamine changed serum immunoreactive trypsin and pancreatic lipase activity.

Patients and methods

Thirty three patients (three men and 30 women) with histologically confirmed primary biliary cirrhosis12 were included in the study. The median age was 59 years (range 49–70). Plasma alkaline phosphatase activity was raised in all the patients (median 517; range 217–2008 U/l), and plasma bilirubin was raised (> 17 μmol/l) in 15 patients. The reference ranges for plasma alkaline phosphatase activity and bilirubin concentration in our routine chemical pathology laboratory are 35–130 U/l and 5–17 μmol/l, respectively.

COLLECTION OF BLOOD SAMPLES AND ASSAYS

Venous blood was obtained without stasis during outpatient follow up visits. Blood was allowed to clot and the serum separated and stored at −20°C. Serum immunoreactive trypsin was measured by radioimmunoassay (double antibody technique) using a kit (Hoechst, Hounslow, United Kingdom).2,4 Serum pancreatic lipase activity was measured3 using a kit (Boehringer, Lewes, Sussex, United Kingdom) based on a turbidimetric method in which a triolein suspension is the substrate. The serum was stored at −20°C until the time of assay in a single batch. In our previous experience2–10 we found immunoreactive trypsin and pancreatic lipase activity values to be stable at this temperature for up to six months, provided the samples were not thawed.

Blood was also collected in heparinised tubes and the plasma assayed for total bilirubin, albumin, and alkaline phosphatase activity using a SMAC-Technicon autoanalyser. These assays were carried out on the same day as the outpatient visit. The reference range for plasma albumin was 35–50 g/l. The
(73%) patients either serum immunoreactive trypsin or pancreatic lipase activity, or both, were raised. The median immunoreactive trypsin concentration (395 μg/l) was at the upper end of the normal range, while the median pancreatic lipase activity (210 U/l) was greater than the upper end of the normal range (Figure). Serum immunoreactive trypsin was subnormal in one patient (3%) who had concomitant insulin dependent diabetes. Although some patients had a raised immunoreactive trypsin concentration with normal pancreatic lipase activity, or vice versa, there was a significant correlation between immunoreactive trypsin and pancreatic lipase activity (r = 0.56; p < 0.01).

There was no significant correlation between serum immunoreactive trypsin or pancreatic lipase activity and indices of liver function: plasma alkaline phosphatase activity, plasma bilirubin, or plasma albumin concentrations. Some patients with total plasma bilirubin concentrations within the normal range had raised serum immunoreactive trypsin concentrations and pancreatic lipase activity (Table). The stage of the disease12 (Table), the presence of “sicca” syndrome12 (such as dry eyes and mouth with or without arthritis), and D-penicillamine treatment did not affect pancreatic enzymes.

The median immunoreactive trypsin concentration in patients with primary biliary cirrhosis below the age of 59 (the median age of these patients) was 470 μg/l, which was higher (though not significantly higher) than in patients whose age was more than 59 (326 μg/l). Similarly, the median pancreatic lipase activity in patients below the age of 59 was 245 U/l, which was higher (though not significantly higher) than in patients whose age was above 59 (214 U/l).

**Discussion**

This study shows that either serum immunoreactive trypsin concentration or pancreatic lipase activity are above normal in 73% of patients with primary biliary cirrhosis. The only patient who had a subnormal immunoreactive trypsin concentration had concomitant insulin dependent diabetes mellitus, a condition in which we have previously reported subnormal activities of this enzyme.4

We have shown previously that pancreatic enzyme

---

**Serum immunoreactive trypsin and pancreatic lipase activity (median and range) in patients with primary biliary cirrhosis**

<table>
<thead>
<tr>
<th>D-penicillamine</th>
<th>“Sicca”12</th>
<th>Stage</th>
<th>Bilirubin (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yes</strong> (n = 13)</td>
<td><strong>No</strong> (n = 8)</td>
<td><strong>Early</strong> (n = 8)</td>
<td><strong>Late</strong> (n = 15)</td>
</tr>
<tr>
<td>Immunoreactive trypsin (μg/l)</td>
<td>439 (100-968)</td>
<td>347 (172-1353)</td>
<td>402 (174-1353)</td>
</tr>
<tr>
<td>Pancreatic lipase (U/l)</td>
<td>210 (91-1300)</td>
<td>198 (63-935)</td>
<td>230 (86-1300)</td>
</tr>
</tbody>
</table>

**Early” primary biliary cirrhosis is defined as stage I and stage II on hepatic histology12; “late” primary biliary cirrhosis as stages III and IV.**

---

**Figure**  Serum immunoreactive trypsin concentration and pancreatic lipase activity in patients with primary biliary cirrhosis. Parentheses show normal range.

Reference ranges in our laboratory for serum immunoreactive trypsin and pancreatic lipase activity in adults are 140–400 μg/l and 50–200 U/l, respectively.

Statistical analysis was carried out using the Mann-Whitney U test (two tailed) for non-parametric data. Correlation studies were done using linear regression analysis.

**Results**

Serum immunoreactive trypsin concentrations were raised (above the normal range) in 16 (48%) patients and serum pancreatic lipase activity was raised in 18 (55%). In 10 (30%) both immunoreactive trypsin and pancreatic lipase activity were raised. Thus in 24
activity may be increased in the absence of clinically overt pancreatitis in the elderly; in patients with cystic fibrosis or thalassaemia major, and in those receiving high doses of methylprednisolone. This abnormality was thought to reflect a breakdown of the “acinar-blood barrier,” with consequent leakage of pancreatic enzymes and their proenzymes into the blood.

The increased pancreatic enzymes in patients with primary biliary cirrhosis are unlikely to be caused by an age related phenomenon. The median immunoreactive trypsin and pancreatic lipase activity in patients below the age of 59 was higher than that in patients above 59 years. Furthermore, our normal range is based on a large population up to the age of 65. In addition, the elderly patients included in our study reporting increased activities of pancreatic enzymes were much older (median age 77.5 years, range 67–98 years) than the patients with primary biliary cirrhosis in this study (median age 59 years, range 49–70 years).

Cholestasis is unlikely to have made a major contribution to the raised pancreatic enzyme activities, as there was no correlation between serum immunoreactive trypsin or pancreatic lipase activity and plasma bilirubin or alkaline phosphatase in this study, and patients with raised pancreatic enzyme activities had normal, mildly, or severely raised plasma bilirubin concentrations.

Patients treated with D-penicillamine had higher immunoreactive trypsin concentrations than untreated patients. Although this difference was not significant, it is relevant that cases of acute pancreatitis associated with D-penicillamine treatment have been reported. Animal experiments have also shown that this drug causes exocrine pancreatic dysfunction.

Serum immunoreactive trypsin and pancreatic lipase activity did not differ when patients were classified according to their stage of disease as determined by liver biopsy. This suggests that pancreatic damage is not dependent on, and does not parallel, histological changes in the liver.

Although there was a significant correlation between serum immunoreactive trypsin and pancreatic lipase activity in our patients, both enzymes were often not concomitantly raised. This discrepancy is probably due to the fact that the immunoreactive trypsin radioimmunoassay also measures trypsinogen; pancreatic lipase activity estimation, on the other hand, is based on enzymatic activity only. We have previously observed a similar discrepancy between immunoreactive trypsin and pancreatic lipase activity in β-thalassaemia major with iron overload.

Our findings of raised immunoreactive trypsin and primary biliary cirrhosis concentrations can be interpreted as evidence that exocrine pancreatic damage occurs in a large proportion of patients with primary biliary cirrhosis. This assumption is based on the finding of raised serum concentrations of immunoreactive trypsin and pancreatic lipase activity in acute pancreatitis, in early cystic fibrosis—that is, preceding the well documented functional pancreatic failure which occurs in this disease—and following the administration of high doses of methylprednisolone (which are thought to be a risk factor for acute pancreatitis). Pancreatic secretion of enzymes following stimulation with secretin-pancreozymin has also been shown to be impaired in primary biliary cirrhosis.

The mechanism causing the postulated pancreatic damage is not clear, but it is probably not directly related either to the histological changes in the liver, treatment with D-penicillamine, or the degree of abnormality of liver function.

We thank Pamela Dale for secretarial help.

References


Requests for reprints to: Dr P Dandona, Metabolic Unit, Department of Chemical Pathology and Human Metabolism, Royal Free Hospital and School of Medicine, London NW3 2QG, England.
Serum immunoreactive trypsin and pancreatic lipase in primary biliary cirrhosis.

V Fonseca, O Epstein, A Katrak, D Junglee, D P Mikhailidis, N McIntyre and P Dandona

doi: 10.1136/jcp.39.6.638

Updated information and services can be found at:
http://jcp.bmj.com/content/39/6/638

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/